Wouter Haazen

915 citations
28 papers · 669 · h-index 14

Impact in

  • Internal Medicine top 5%
    • Venous Thromboembolism Diagnosis and Management
  • Infectious Diseases top 10%
    • HIV/AIDS drug development and treatment
    • Viral gastroenteritis research and epidemiology
    • HIV/AIDS Research and Interventions

Papers in

Co-authors
Marina De Smet (3 shared papers)Viktoria Moschetti (4 shared papers)Jeremy Nuttall (2 shared papers)Stephan Glund (4 shared papers)Annaléne Nel (2 shared papers)Neliëtte van Niekerk (2 shared papers)Joachim Stangier (4 shared papers)Benjamin Lang (4 shared papers)
Journals
Open Forum Infectious Diseases (5 papers)The Journal of Infectious Diseases (3 papers)Journal of Hepatology (2 papers)Journal of Crohn s and Colitis (2 papers)The Journal of Clinical Pharmacology (2 papers)
Partner nations
United StatesBelgiumNetherlands

In The Last Decade

Wouter Haazen

28 papers receiving 648 citations

Peers

Wouter Haazen
Comparison fields: 5 of 71
  • Internal Medicine 60
  • Infectious Diseases 188
  • Microbiology 65
  • Endocrinology 48
  • Virology 40
Replace Emile F. Schippers with:
Emile F. Schippers Netherlands
Meliha Meriç Koç Türkiye
Sun Bean Kim South Korea
Marielle Buisson France
Michael Dalager‐Pedersen Denmark
Fernando Ballester Laguna Spain
Felix Lötsch Austria
Pieter J. van den Broek Netherlands
B Becq-Giraudon France
Novella Carannante Italy
Wouter Haazen relative to Emile F. Schippers Netherlands Emile F. Schippers's profile →
Citations per field
00.5×2×3×4×4.6×
Emile F. Schippers · 1×
Citations per year

Countries citing papers authored by Wouter Haazen

Since Specialization
Citations

This map shows the geographic impact of Wouter Haazen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wouter Haazen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wouter Haazen more than expected).

Fields of papers citing papers by Wouter Haazen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wouter Haazen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wouter Haazen. The network helps show where Wouter Haazen may publish in the future.

Co-authors

The 25 scholars most cited alongside Wouter Haazen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wouter Haazen Line = papers co-authored together Wouter Haazen links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study
The Journal of Infectious Diseases ·Jerald Sadoff, Els De Paepe, John P. DeVincenzo, Efi Gymnopoulou, Joris Menten, Bryan Murray, Arangassery Rosemary Bastian, An Vandebosch, Wouter Haazen, Nicolas Noulin, Christy Comeaux, Esther Heijnen, Kingsley Eze, Anthony Gilbert, Rob Lambkin‐Williams, Hanneke Schuitemaker, Benoît Callendret
202168
2
A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
AIDS ·Annaléne Nel, Wouter Haazen, Jeremy Nuttall, Joseph Romano, Zeda Rosenberg, Neliëtte van Niekerk
201461
3
Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects
Blood ·Stephan Glund, Joachim Stangier, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Ganßer, Stephen H. Norris, Benjamin Lang, Paul Reilly
201459
4
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial
The Lancet Infectious Diseases ·Robert W. Frenck, John Ervin, Laurence Chu, Darren Abbanat, Bart Spiessens, Oscar Go, Wouter Haazen, Germie van den Dobbelsteen, Jan Poolman, S Thoelen, Patricia Palacios
201959
5
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
Clinical Pharmacokinetics ·Stephan Glund, Joachim Stangier, Joanne van Ryn, Michael Schmohl, Viktoria Moschetti, Wouter Haazen, Marina De Smet, Dietmar Ganßer, Stephen H. Norris, Benjamin Lang, Paul Reilly, Jörg Kreuzer
201659
6
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Antimicrobial Agents and Chemotherapy ·Marian Iwamoto, Larissa Wenning, Amelia S. Petry, Martine E. Laethem, Marina De Smet, James Kost, Sheila Breidinger, Eric Mangin, Neal Azrolan, Howard Greenberg, Wouter Haazen, Julie A. Stone, Keith Gottesdiener, John A. Wagner
200853
7
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults
The Journal of Infectious Diseases ·Jerald Sadoff, Els De Paepe, Wouter Haazen, Edmund Omoruyi, Arangassery Rosemary Bastian, Christy Comeaux, Esther Heijnen, Cynthia Strout, Hanneke Schuitemaker, Benoît Callendret
202042
8
Multiple‐Dose Administration of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Alter the Single‐Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects
The Journal of Clinical Pharmacology ·Goutam C. Mistry, Arthur Bergman, Wen‐Lin Luo, Caroline Cilissen, Wouter Haazen, Michael J. Davies, Keith Gottesdiener, John A. Wagner, Gary Herman
200741
9
A human anti‐D monoclonal antibody selected for enhanced FcγRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti‐D antibodies
British Journal of Haematology ·R Béliard, Tony Waegemans, Dominique Notelet, Léna Massad, F. Dhainaut, Christophe de Romeuf, Eric Guémas, Wouter Haazen, Dominique Bourel, Jean‐Luc Teillaud, Jean‐François Prost
200830
10
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
The Journal of Infectious Diseases ·Arabella Stuart, Miia Virta, Kristi L. Williams, Ilkka Seppä, Robyn Hartvickson, Melanie Greenland, Edmund Omoruyi, Arangassery Rosemary Bastian, Wouter Haazen, Nadine C. Salisch, Efi Gymnopoulou, Benoît Callendret, Saul N. Faust, Matthew D. Snape, Esther Heijnen
202229
11
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
The Journal of Clinical Pharmacology ·Rajesh Krishna, Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow, Isaias Noel Gendrano, Martine Robberechts, Wouter Haazen, Jan de Hoon, Marleen Depré, Ashley Martucci, Joanna Peng, Amy O. Johnson‐Levonas, John A. Wagner, S. Aubrey Stoch
201629
12
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults
Vaccine ·Geert Leroux‐Roels, Pierre Van Damme, Wouter Haazen, Sepehr Shakib, Magalie Caubet, Emmanuel Aris, Jeanne‐Marie Devaster, Mathieu Peeters
201628
13
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study
Open Forum Infectious Diseases ·Carlos Fierro, Michal Sarnecki, Joachim Doua, Bart Spiessens, Oscar Go, Todd A. Davies, Germie van den Dobbelsteen, Jan Poolman, Darren Abbanat, Wouter Haazen
202319
14
Pharmacokinetics and Safety Assessment of Anti-HIV Dapivirine Vaginal Microbicide Rings with Multiple Dosing
Journal of AIDS & Clinical Research ·Wouter Haazen
201419
15
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
British Journal of Clinical Pharmacology ·Stephen H. Norris, Steven Ramael, Ippei Ikushima, Wouter Haazen, Akiko Harada, Viktoria Moschetti, Susumu Imazu, Paul Reilly, Benjamin Lang, Joachim Stangier, Stephan Glund
20179
16
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI
npj Vaccines ·Carlos Fierro, Michal Sarnecki, Bart Spiessens, Oscar Go, Tracey Day, Todd A. Davies, Germie van den Dobbelsteen, Jan Poolman, Darren Abbanat, Wouter Haazen
20248
17
902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
Open Forum Infectious Diseases ·John P. DeVincenzo, Efi Gymnopoulou, Els De Paepe, Bryan Murray, Arangassery Rosemary Bastian, Wouter Haazen, Nicolas Noulin, Christy Comeaux, Esther Heijnen, Kinglsey Eze, Anthony Gilbert, Rob Lambkin‐Williams, Hanneke Schuitemaker, Benoît Callendret, Jerald Sadoff
20198
18
Drug-drug Interactions between the Dapivirine Vaginal Ring (Ring-004) and Miconazole Nitrate Vaginal Capsule (Gyno-Daktarin ® )
AIDS Research and Human Retroviruses ·Annaléne Nel, Wouter Haazen, Marisa Russell, Jeremy Nuttall, Neliëtte van Niekerk, Nicoline Treijtel
20148
19
2012 VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS
Journal of Hepatology ·V. Detishin, Wouter Haazen, H. Robison, L. Robarge, Elizabeth Olek
20108
20
2712. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants
Open Forum Infectious Diseases ·William B. Smith, Darren Abbanat, Bart Spiessens, Oscar Go, Wouter Haazen, Tiziano de Rosa, Kellen C. Faé, Jan Poolman, S Thoelen, Patricia Palacios
20197

About Wouter Haazen

Wouter Haazen is a scholar working on Epidemiology, Endocrinology, Infectious Diseases, Molecular Biology and Microbiology, having authored 28 papers that have together received 669 indexed citations. Recurring topics across this work include Escherichia coli research studies (6 papers), Respiratory viral infections research (5 papers), Diabetes Treatment and Management (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Reproductive tract infections research (3 papers), Bacterial Infections and Vaccines (2 papers), Viral gastroenteritis research and epidemiology (2 papers) and HIV/AIDS drug development and treatment (2 papers). The work is most often cited by research in Internal Medicine (60 citations), Infectious Diseases (188 citations), Microbiology (65 citations), Endocrinology (48 citations) and Virology (40 citations). Wouter Haazen has collaborated with scholars based in United States, Belgium and Netherlands. Frequent co-authors include Marina De Smet, Viktoria Moschetti, Jeremy Nuttall, Stephan Glund, Annaléne Nel, Neliëtte van Niekerk, Joachim Stangier, Benjamin Lang, Stephen H. Norris and Paul Reilly. Their work appears in journals such as Open Forum Infectious Diseases, The Journal of Infectious Diseases, Journal of Hepatology, Journal of Crohn s and Colitis and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emile F. SchippersBreakdown of academic impact, for papers by Meliha Meriç KoçBreakdown of academic impact, for papers by Sun Bean KimBreakdown of academic impact, for papers by Marielle BuissonBreakdown of academic impact, for papers by Michael Dalager‐PedersenBreakdown of academic impact, for papers by Fernando Ballester LagunaBreakdown of academic impact, for papers by Felix LötschBreakdown of academic impact, for papers by Pieter J. van den BroekBreakdown of academic impact, for papers by B Becq-GiraudonBreakdown of academic impact, for papers by Novella Carannante